Antimicrobial Resistance of Streptococcus pneumoniae Clinical Serotypes between 2017 and 2022 in Crete, Greece
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background Pneumococcal disease is still considered a global problem. With the introduction of pneumococcal conjugate vaccines (PCVs) serotype epidemiology changed, but antimicrobial resistance persists constituting a serious problem. The current study aimed to determine the serotype distribution and the antimicrobial susceptibility of recent Streptococcus pneumoniae isolates, following implementation of the 13-valent conjugate vaccine (PCV13). Materials and Methods From January 2017 to December 2022 we evaluated 116 nonduplicate S. pneumoniae isolates collected from adult patients (21 - 98 years) cared for in the University Hospital of Heraklion, Crete, Greece. Pneumococcal isolates were serotyped by the Quellung reaction, and antimicrobial susceptibility testing was performed using E-test. Multidrug resistance (MDR) was defined as non-susceptibility to at least one agent in ≥3 classes of antibiotics. Results Among the 116 isolates, 31% were recognized as invasive pneumococcal strains, while 69% were non-invasive. The isolates tested belonged to 25 different serotypes. The most prevalent serotypes were 11A (10.3%), and 35B (10.3%), followed by 3 (9.5%), 15A (7.8%), 25F (6.9%), 19A (5.3%), 35F (5.3%), and others (44.6%). The coverage rates of PCV13 and the pneumococcal polysaccharide vaccine (PPSV23) were 26.7% and 57.8%, respectively. PCV13 and PPSV23 serotypes decreased between 2017 - 2019 and 2020 - 2022, with a parallel increase in the non-vaccine types. Resistance rates to erythromycin, clindamycin, trimethoprim/sulfamethoxazole, penicillin, levofloxacin, and ceftriaxone, were 40.5%, 21.6%, 13.8%, 12.1%, 3.4%, and 0%, respectively. All isolates were susceptible to vancomycin, linezolid, and daptomycin. MDR was observed among 36 (31%) S. pneumoniae isolates. Conclusion The increasing levels of resistance in S. pneumoniae in Crete, Greece, highlight the need for continuous surveillance of antimicrobial resistance and development of strategies for its reduction, including antimicrobial stewardship programs, increased pneumococcal vaccination, and development of next generation PCVs with a wider serotype coverage.
Abstract
Background Pneumococcal disease is still considered a global problem. With the introduction of pneumococcal conjugate vaccines (PCVs) serotype epidemiology changed, but antimicrobial resistance persists constituting a serious problem. The current study aimed to determine the serotype distribution and the antimicrobial susceptibility of recent Streptococcus pneumoniae isolates, following implementation of the 13-valent conjugate vaccine (PCV13). Materials and Methods From January 2017 to December 2022 we evaluated 116 nonduplicate S. pneumoniae isolates collected from adult patients (21 - 98 years) cared for in the University Hospital of Heraklion, Crete, Greece. Pneumococcal isolates were serotyped by the Quellung reaction, and antimicrobial susceptibility testing was performed using E-test. Multidrug resistance (MDR) was defined as non-susceptibility to at least one agent in ≥3 classes of antibiotics. Results Among the 116 isolates, 31% were recognized as invasive pneumococcal strains, while 69% were non-invasive. The isolates tested belonged to 25 different serotypes. The most prevalent serotypes were 11A (10.3%), and 35B (10.3%), followed by 3 (9.5%), 15A (7.8%), 25F (6.9%), 19A (5.3%), 35F (5.3%), and others (44.6%). The coverage rates of PCV13 and the pneumococcal polysaccharide vaccine (PPSV23) were 26.7% and 57.8%, respectively. PCV13 and PPSV23 serotypes decreased between 2017 - 2019 and 2020 - 2022, with a parallel increase in the non-vaccine types. Resistance rates to erythromycin, clindamycin, trimethoprim/sulfamethoxazole, penicillin, levofloxacin, and ceftriaxone, were 40.5%, 21.6%, 13.8%, 12.1%, 3.4%, and 0%, respectively. All isolates were susceptible to vancomycin, linezolid, and daptomycin. MDR was observed among 36 (31%) S. pneumoniae isolates. Conclusion The increasing levels of resistance in S. pneumoniae in Crete, Greece, highlight the need for continuous surveillance of antimicrobial resistance and development of strategies for its reduction, including antimicrobial stewardship programs, increased pneumococcal vaccination, and development of next generation PCVs with a wider serotype coverage.
참고문헌 (36)
- Janoff EN, "Mandell, Douglas, and Bennett's principles and practice of infectious diseases", pp.2473~2491 (2020), Elsevier
- O’Brien KL, "Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years : global estimates", Lancet, 374, pp.893~902 (2009)
- "Invasive pneumococcal disease: annual epidemiological report for 2018"[URL]
- Chen H, "Prognostic factors for mortality in invasive pneumococcal disease in adult : a system review and meta-analysis", Sci Rep, 11, pp.11865~ (2021)
- Hansman D, "A resistant pneumococcus", Lancet, 277, pp.264~265 (1967)
- Antimicrobial resistance: global report on surveillance, "World Health Organization(WHO)", WHO, ~ (2014)
- "National immunization program for adults" (2011)[URL]
- "National immunization program for adults 2015"[URL]
- Papagiannis D, "Vaccination coverage of the elderly in Greece : a cross-sectional nationwide study", Can J Infect Dis Med Microbiol, 2020, pp.5459793~ (2020)
- Maraki S, "Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece", Int J Antimicrob Agents, 17, pp.465~469 (2001)
- Clinical and Laboratory Standards Institute (CLSI), "Performance standards for antimicrobial susceptibility testing" (2022), CLSI
- Pfizer,Inc, "Tigecycline, package insert", ~ (2012)
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Maraki S, "The evolving epidemiology of serotype distribution and antimicrobial resistance of Streptococcus pneumoniae strains isolated from adults in Crete, Greece, 2009-2016", Infect Chemother, 50, pp.328~339 (2018)
- Kim L, "Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre-and post-conjugate vaccine eras : a United States perspective", Clin Microbiol Rev, 29, pp.525~552 (2016)
- Demczuk WHB, "Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016", Vaccine, 36, pp.4701~4707 (2018)
- Sheppard C, "Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014", Euro Surveill, 21, pp.30423~ (2016)
- Ubukata K, "Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010-2017", Emerg Infect Dis, 24, pp.2010~2020 (2018)
- Nakano S, "Nationwide surveillance of paediatric invasive and non-invasive pneumococcal disease in Japan after the introduction of the 13-valent conjugated vaccine, 2015-2017", Vaccine, 38, pp.1818~1824 (2020)
- Teixeira R, "Pneumococcal serotype evolution and burden in European adults in the last decade : a systematic review", Microorganisms, 11, pp.1376~ (2023)
- Skoczyńska A, "Recent trends in epidemiology of invasive pneumococcal disease in Poland", Eur J Clin Microbiol Infect Dis, 34, pp.779~787 (2015)
- Vestjens SMT, "Twelve years of pneumococcal conjugate vaccination in the Netherlands : Impact on incidence and clinical outcomes of invasive pneumococcal disease", Vaccine, 37, pp.6558~6565 (2019)
- Navarro-Torné A, "Risk factors for death from invasive pneumococcal disease, Europe, 2010", Emerg Infect Dis, 21, pp.417~425 (2015)
- Galanis I, "Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden", Eur Respir J, 47, pp.1208~1218 (2016)
- van der Linden M, "Limited indirect effects of an infant pneumococcal vaccination program in an aging population", PLoS One, 14, pp.e0220453~ (2019)
- González-Díaz A, "Emerging non-13-valent pneumococcal conjugate vaccine(PCV13)serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain", Clin Microbiol Infect, 26, pp.753~759 (2020)
- Andrews NJ, "Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine : a postlicensure indirect cohort study", Lancet Infect Dis, 14, pp.839~846 (2014)
- Moore MR, "Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA : analysis of multisite, population-based surveillance", Lancet Infect Dis, 15, pp.301~309 (2015)
- Maraki S, "Serotype distribution and antimicrobial resistance of adult Streptococcus pneumoniae clinical isolates over the period 2001-2008 in Crete, Greece", Chemotherapy, 56, pp.325~332 (2010)
- Woodhead M, "Guidelines for the management of adult lower respiratory tract infections--full version", Clin Microbiol Infect, 17(Suppl 6), pp.E1~E59 (2011)
- van de Beek D, "ESCMID guideline : diagnosis and treatment of acute bacterial meningitis", Clin Microbiol Infect, 22(Suppl 3), pp.S37~S62 (2016)
- Li XX, "Serotype distribution, antimicrobial susceptibility, and multilocus sequencing type(MLST)of Streptococcus pneumoniae from adults of three hospitals in Shanghai, China", Front Cell Infect Microbiol, 9, pp.407~ (2019)
- Tsai YT, "Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019", J Microbiol Immunol Infect, 55, pp.215~224 (2022)
- Kim GR, "Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing Invasive pneumococcal disease in Korea between 2017 and 2019 after introduction of the 13-valent pneumococcal conjugate vaccine", Ann Lab Med, 43, pp.45~54 (2023)
- Mohanty S, "A Multicenter evaluation of trends in antimicrobial resistance among Streptococcus pneumoniae isolates from adults in the United States", Open Forum Infect Dis, 9, pp.ofac420~ (2022)
- Park DC, "Serotype distribution and antimicrobial resistance of invasive and noninvasive Streptococcus pneumoniae isolates in Korea between 2014 and 2016", Ann Lab Med, 39, pp.537~544 (2019)